GRCE

Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing drug candidates for rare and orphan diseases, particularly in the field of neurology. Its lead product, GTx-104, is a reformulation of nimodipine designed for intravenous infusion to treat aneurysmal subarachnoid hemorrhage (aSAH), addressing the limitations of the oral administration of the drug. The company has received Orphan Drug Designation from the FDA for its clinical assets and holds a comprehensive intellectual property portfolio.